Literature DB >> 1101946

Effect of bromocriptine and chlorotrianisene on inhibition of lactation and serum prolactin. A comparative double-blind study.

W H Utian, G Begg, A I Vinik, M Paul, L Shuman.   

Abstract

A double-blind study to compare the effect of 2-Br-alpha-ergocryptine (bromocriptine, CB 154, Sandoz) an ergot alkaloid with chlorotrianisene (Tace, Mer-National) on the inhibition of postpartum lactation was carried out in 38 women. At the dosages selected bromocriptine was more effective than chlorotrianisene in inhibiting lactation. Furthermore, bromocriptine significantly reduced serum prolactin levels to low normal values by the seventh day of treatment, whereas chlorotrianisene did not alter the normal progressive reduction in prolactin post-partum. Neither drug had significant toxic effects.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1101946     DOI: 10.1111/j.1471-0528.1975.tb00718.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  7 in total

Review 1.  Treatments for suppression of lactation.

Authors:  Olufemi T Oladapo; Bukola Fawole
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 2.  Use of bromocriptine in the inhibition of puerperal lactation.

Authors:  R Rolland
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

3.  Efficacy of bromocriptine and chlorotrianisene in preventing postpartum lactation.

Authors:  B H Yuen; H J Pendleton; S Blair
Journal:  Can Med Assoc J       Date:  1977-10-22       Impact factor: 8.262

Review 4.  Breast Cancer and Prolactin - New Mechanisms and Models.

Authors:  Charles V Clevenger; Hallgeir Rui
Journal:  Endocrinology       Date:  2022-10-01       Impact factor: 5.051

5.  Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women.

Authors:  P L Venturini; R Horowski; M Valenzano; S Costantini; V Fasce; F Gorlero; E Rainer; L De Cecco
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  The endocrine profile of bromocriptine: its application in endocrine diseases.

Authors:  I Lancranjan
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers.

Authors:  Yunguang Sun; Ning Yang; Fransiscus E Utama; Sameer S Udhane; Junling Zhang; Amy R Peck; Alicia Yanac; Katherine Duffey; John F Langenheim; Vindhya Udhane; Guanjun Xia; Jess F Peterson; Julie M Jorns; Marja T Nevalainen; Romain Rouet; Peter Schofield; Daniel Christ; Christopher J Ormandy; Anne L Rosenberg; Inna Chervoneva; Shirng-Wern Tsaih; Michael J Flister; Serge Y Fuchs; Kay-Uwe Wagner; Hallgeir Rui
Journal:  Sci Adv       Date:  2021-09-15       Impact factor: 14.136

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.